Individual Study / DFCI

Genomic data with clinical outcome data from routine practice data from Dana-Farber Cancer Institute, Boston, MA, USA

Genomic data with clinical outcome data from routine practice data from Dana-Farber Cancer Institute, Boston, MA, USA

DFCI logo
Initiatives -
To answer questions about new cancer therapies, including: what diseases should they be used for? What doses of new drugs are most effective? And which patients can benefit the most from them?
Visit DFCI

Members

Download
Investigators Contacts
  • President and CEO Laurie H. Glimcher
    Dana-Farber Cancer Institute

Design

Study design
Patients' cohort

Recruitment

Sources of Recruitment
  • Individuals

Number of participants

Number of participants
Number of participants with biosamples

Access

Availability of data and biosamples

Data
Biosamples
Other